In preclinical studies, all-trans retinoic acid has been used to increase folate receptor β (FRβ) in AML [111], while bryostatin can increase CD22 expression B cell leukemia and lymphoma cells, and it seems to prevent the emergence of low CD22 variant subclones [110,112]. The gene discussed is FOLR2; the disease is acute myeloid leukemia.